布地奈德/福莫特罗维持缓解治疗与哮喘控制:试验启示
本文综述6-12个月双盲RCT及开放标签真实世界研究,比较布地奈德/福莫特罗维持缓解治疗(MART)与ICS/LABA加SABA方案。MART在相似或更高ICS剂量下达到相同或更好症状控制,急性发作率更低,口服激素年需求量明显减少,且在MART方案下急性发作减少40-50%;SYGMA研究显示按需布地奈德/福莫特罗在轻度哮喘中较单用SABA减少急性发作达64%。
要点
- MART在相似或更高ICS剂量下症状控制不劣于或优于ICS/LABA加SABA。
- MART急性发作率更低,口服激素年需求量明显减少。
- 按需布地奈德/福莫特罗在轻度哮喘中较单用SABA减少急性发作达64%。
核心结论
- 布地奈德/福莫特罗MART在相似或更高ICS剂量下达到相同或更好哮喘症状控制,且急性发作率和口服激素需求更低。
研究设计与样本
- 综述已发表的6-12个月双盲随机对照试验和开放标签真实世界研究,涉及布地奈德/福莫特罗MART及相关对照方案。
主要发现
- 与ICS/LABA加SABA方案相比,MART在相似或更高ICS剂量下症状控制相同或更好,急性发作率持续更低,口服激素年需求量明显更低。
- MART方案下,维持剂量确保日常控制,出现症状时使用兼具抗炎作用的缓解药(布地奈德/福莫特罗)补充ICS,较ICS基础治疗加按需SABA使急性发作减少40-50%。
- SYGMA研究显示,按需布地奈德/福莫特罗在轻度哮喘中较单用SABA更有效,急性发作减少达64%。
关键数值与推荐
- MART较ICS基础治疗加按需SABA使急性发作减少40-50%。
- SYGMA研究中按需布地奈德/福莫特罗较单用SABA减少急性发作达64%。
临床怎么用
- 对持续哮喘患者可考虑布地奈德/福莫特罗MART方案,以改善症状控制并降低急性发作和口服激素需求。
- 轻度哮喘患者按需使用布地奈德/福莫特罗可作为单用SABA的替代缓解策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite improvements in medications, devices and understanding of the disease, about half of all asthma patients worldwide remain inadequately controlled, suggesting the need for a new approach to asthma management. Poor adherence to prescribed maintenance therapy and over-reliance on SABA reliever medication is a common cause of inadequate control. This article reviews published data from 6- to 12-month, double-blind, RCT and open-label real-world studies involving budesonide/formoterol maintenance and reliever therapy (MART) and relevant comparator approaches to asthma management, and considers how these compare in achieving the treatment goals described in guidelines. The data confirm that patients with asthma treated with budesonide/formoterol MART achieved the same or better asthma symptom control compared with ICS/LABA plus SABA regimens at similar or higher ICS doses, with consistently lower rates of exacerbations and considerably lower annual requirement for oral corticosteroids. These findings have been confirmed across a range of severities of persistent asthma. With the MART approach, maintenance dosing ensures coverage for day-to-day control, and the use of a reliever with anti-inflammatory properties (budesonide/formoterol) provides extra doses of ICS as soon as symptoms prompt the use of reliever, resulting in a 40-50% reduction of exacerbations compared with an ICS-based treatment approach plus as-needed SABA as reliever. As-needed, budesonide/formoterol has also recently been shown to be more effective as a reliever in mild asthma than SABA alone, reducing exacerbations by up to 64% in the SYGMA studies.
引用
- Jenkins CR, Bateman ED, Sears MR, et al. What have we learnt about asthma control from trials of budesonide/formoterol as maintenance and reliever? Respirology. 2020. PMID: 32237004. doi:10.1111/resp.13804
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。